Top 20 Generics Pharma Companies Based On 2020 Revenue

Shots:Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength- effect- dosage form- and route of administration. These are allowed for sale after the patent expiry of the original drugsOur team at PharmaShots has compiled a list of the top 20 generic companies based on…

ByPrince GiriOctober 28, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of July 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of Jul, Viatris & Biocon's Semglee got the US…

BySenior EditorAugust 5, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of March 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of March, Samsung Bioepis Initiated P-I Study of SB17…

BySenior EditorApril 1, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of February 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of Feb, Biocon collaborated with CHAI to expand access…

BySenior EditorMarch 4, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyMylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar,…

BySenior EditorSeptember 3, 2020

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2020

The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche's Phesgo and Enspryng & Zogenix's Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The…

BySenior EditorJuly 7, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyMylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectivelyOur team at PharmaShots has summarized 15 key events of the…

BySenior EditorJuly 3, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of April 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…

BySenior EditorMay 8, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of March 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyHence, the providers are more likely to adopt biosimilars as a 'reference product to biologics' possessing similar therapeutic propertiesThe US FDA took an initiative to develop new pathways for Insulin biosimilars. Our team at PharmaShots has…

BySenior EditorApril 10, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of December 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyIn Dec, 2019 Kamada signed a deal with Alvotech for commercialization of biosimilars in Israel while Techno Science also signed an agreement with Kishi Kasei for co-developing biosimilar afliberceptMylan and Biocon launched its Ogivri (trastuzumab-dkst) in…

BySenior EditorJanuary 17, 2020

Top 20 Generics Pharma Companies Based On 2020 Revenue

Insights+ Key Biosimilars Events of July 2021

Insights+ Key Biosimilars Events of March 2021

Insights+ Key Biosimilars Events of February 2021

Insights+ Key Biosimilars Events of August 2020

PharmaShots’ Key Highlights of Second Quarter 2020

Insights+ Key Biosimilars Events of June 2020

Insights+ Key Biosimilars Events of April 2020

Insights+ Key Biosimilars Events of March 2020

Insights+ Key Biosimilars Events of December 2019

Contact US

OUR INFORMATION

FOLLOW US